PTPN4 and breast cancer: Although MeG exhibited better activity in ER+ breast cancer cells, transcriptomic analysis showed no significant effects of MeG on the expression of estrogen receptor 1 or 2 and no significant effects on estrogen-dependent cancer signaling pathways.